

Publication of Annual Report and Notice of AGM

RNS Number : 0688P

Novacyt S.A.

23 May 2018

Publication of Annual Report and Notice of AGM

Paris, France and Camberley, UK - 23 May 2018 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces that the Company's Annual Report and Accounts ("Annual Report") for the year ended 31 December 2017 has today been published and uploaded to the Company's website. The Annual Report has also been posted in hard copy to all shareholders that hold ordinary shares through CREST Depository Interests (CDIs). The Notice of the Annual General Meeting (AGM) and a Form of Proxy were made available to shareholders on 4 May 2018.

Electronic copies of these documents are available on the Company's website at www.novacyt.com. Alternatively, a hardcopy is available from either 13 Avenue Morane Saulnier, 78140 Vélizy-Villacoubly, France or Unit 1, Watchmoor Point, Watchmoor Road, Camberley, Surrey, GU15 3AD UK or will be posted upon request from investor.relations@novacyt.co.uk.

As previously announced on 26 April 2018, the AGM will be held on 11 June, at 2.00 p.m. (Paris time) Stance Avocats, 37-39 Avenue de, Friedland, Paris, 75008, France.

- End -

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

+44 (0)1223 395472

Stifel Nicolaus Europe Limited (Nominated Advisor and Joint Broker)

Jonathan Senior / Fred Walsh / Ben Maddison

+44 (0)20 7610 7600

WG Partners (Joint Broker)

Nigel Birks / Chris Lee / Claes Spång

+44 (0)203 705 9330

FTI Consulting (International)

Brett Pollard / Victoria Foster Mitchell

+44 (0)20 3727 1000

brett.pollard@fticonsulting.com / victoria.fostermitchell@fticonsulting.com

FTI Consulting (France)

Arnaud de Cheffontaines / Astrid Villette

+33 (0)147 03 69 47 / +33 (0)147 03 69 51

arnaud.decheffontaines@fticonsulting.com / astrid.villette@fticonsulting.com

About Novacyt Group

The Novacyt Group is a rapidly growing, international diagnostics group with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform, NOVAprep®, and molecular platform, genesig®, Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products across an extensive international distributor network. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.

For more information please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NOAPGUBCAUPRGWW